CytomX Therapeutics Inc. Revenue 2013–2025
CytomX Therapeutics Inc. annual/quarterly revenue history and growth rate from 2013 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- CytomX Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 10.3 M, a 79.85% decrease year-over-year.
- CytomX Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 85.8 M, a 32.12% decrease year-over-year.
- CytomX Therapeutics Inc. annual revenue for 2025 was 76.2 M, a 44.82% decrease from 2024.
- CytomX Therapeutics Inc. annual revenue for 2024 was 138.1 M, a 36.45% increase from 2023.
- CytomX Therapeutics Inc. annual revenue for 2023 was 101.2 M, a 90.38% increase from 2022.
- CytomX Therapeutics Inc. annual revenue for 2022 was 53.2 M.
CytomX Therapeutics Inc. (CTMX) — Frequently Asked Questions
CytomX Therapeutics Inc. (CTMX) is a publicly traded US company. It has a market capitalization of $411M. In fiscal 2025 it reported revenue of $76M and net income of -$17M. Explore CTMX's stock price, financial statements, earnings history, margins and key ratios below.
What is CytomX Therapeutics Inc.'s market cap?
CytomX Therapeutics Inc. (CTMX) has a market capitalization of $411M.
What is the CTMX stock price?
CTMX trades at $2.98 (+2.41% on the day).
How much revenue does CytomX Therapeutics Inc. make?
CytomX Therapeutics Inc. reported revenue of $76M in fiscal 2025.
Is CTMX profitable?
In fiscal 2025, CytomX Therapeutics Inc. reported net income of -$17M.